Cite
APA Citation
Califano, R., Każarnowicz, A., Karaseva, N., Sánchez, A., Liu, S. V., Horn, L., Quach, C., Yu, W., Kabbinavar, F., Lam, S., & Mansfield, A. (n.d.). 49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095517995.0x000033